FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma

The U.S. Meals and Drug Administration (FDA) authorised therapy with Monjuvi (tafasitamab-cxix) plus Revlimid (lenalidomide) and Rituxan (rituximab) for adults with relapsed or refractory follicular lymphoma.

The effectiveness of Monjuvi was studied within the double-blind, placebo-controlled inMIND trial which enrolled 548 sufferers with relapsed or refractory illness. Eligbile members have been randomly assigned to obtain both Monjuvi or placebo alongside Revlimid and Rituxan. A lot of the sufferers enrolled on the examine had undergone one earlier systemic therapy, whereas 25% had receoved two prior remedies and 20% had three or extra.

The primary measure of efficacy was investigator-assessed progression-free survival. After 14.1 months of follow-up, progression-free survival was statistically considerably longer with Monjuvi in comparison with placebo, with a median of twenty-two.4 months versus 13.9 months respectively.

Critical unwanted effects occurred in 33% of sufferers receiving Monjuvi, together with severe infections in 24%. The Monjuvi prescribing info consists of warnings for infusion-related reactions, low blood counts, and infections.

The really useful dose of Monjuvi is 12 milligrams per kilogram given by intravenous infusion for as much as 12 cycles with lenalidomide and rituximab. Monjuvi isn’t authorised or really useful for sufferers with relapsed or refractory marginal zone lymphoma exterior of medical trials.

This overview was executed via Venture Orbis, a program from the FDA Oncology Middle of Excellence that helps pace up the overview of most cancers medication by working with regulatory businesses in different nations on the identical time. For this overview, the FDA partnered with Australia’s Therapeutic Items Administration and Well being Canada, that are nonetheless finishing their very own evaluations.

To assist with the method, the FDA used an Evaluation Assist — a voluntary doc from the drug’s maker designed to make the overview smoother.

This software was given precedence overview. Tafasitamab-cxix additionally obtained orphan drug standing for follicular lymphoma. Yow will discover extra about FDA’s expedited packages of their Steering for Trade on Critical Circumstances.

Earlier Efficacy Findings

Monjuvi plus Revlimid and Rituxan lowered the danger of illness development or dying by 57% in contrast with placebo plus Revlimid and Rituxan, in accordance with a section 3 trial introduced on the 2024 ASH Annual Assembly.

At a median follow-up of 14.1 months, median investigator-assessed progression-free survival was 22.4 months with the triplet (273 sufferers) versus 13.9 months with Revlimid and Rituxan alone (275 sufferers).

By unbiased overview committee evaluation, median progression-free survival was not but reached with the triplet versus 16 months with the doublet.

“The inMIND section 3 examine met its main finish level of prolonging PFS in relapsed/refractory follicular lymphoma,” Dr. Laurie H. Sehn mentioned in a presentation of the info. “Profit was noticed in all prespecified subgroups, together with sufferers with POD24 [progression of disease within 24 months of initial diagnosis], [those who were] refractory to prior anti-CD20 monoclonal antibodies, and [those] receiving a number of prior strains of remedy.”

Sehn is a lead examine creator and at present serves as a medical professor of medication, School of Medication, Division of Medical Oncology, on the College of British Columbia, in Vancouver, Canada.

Reference:

“FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma.” Press launch. U.S. Meals and Drug Administration. June 18, 2025.

For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.